Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

What Should Thoracic Surgeons Consider during Surgery for Ground-Glass Nodules?: Lymph Node Dissection

  • Kim, Hong Kwan (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2021.04.16
  • Accepted : 2021.09.02
  • Published : 2021.10.05
Download PDF
⟨ Previous Next ⟩

Abstract

Thoracic surgeons need to be aware of several important points regarding intraoperative lymph node dissection during surgery for non-small cell lung cancer with ground-glass opacities. The first point relates to the need for lymph node dissection during sublobar resection. Since even patients undergoing sublobar resection may benefit from lymph node dissection, it should be selectively performed according to adequate indications, which require further study. Second, there seems to be no difference in postoperative morbidity between systematic sampling and systematic dissection, but the survival benefit from systematic dissection remains unclear. The results of randomized controlled trials on this topic are conflicting, and their evidence is jeopardized by a high risk of bias in terms of the study design. Therefore, further randomized controlled trials with a sound design should investigate this issue. Third, more favorable survival outcomes tend to be positively associated with the number of examined lymph nodes. Minimum requirements for the number of examined lymph nodes in non-small cell lung cancer should be defined in the future. Finally, lobe-specific lymph node dissection does not have a negative prognostic impact. It should not be routinely performed, but it can be recommended in selected patients with smaller, less invasive tumors. Results from an ongoing randomized controlled trial on this topic should be awaited.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. https://doi.org/10.3322/caac.21590
  2. Bille A, Woo KM, Ahmad U, Rizk NP, Jones DR. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. Eur J Cardiothorac Surg 2017;51:674-9. https://doi.org/10.1093/ejcts/ezw400
  3. Cho S, Song IH, Yang HC, Kim K, Jheon S. Predictive factors for node metastasis in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg 2013;96:239-45. https://doi.org/10.1016/j.athoracsur.2013.03.050
  4. Gomez-Caro A, Boada M, Cabanas M, et al. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer. Eur J Cardiothorac Surg 2012;42:93-100. https://doi.org/10.1093/ejcts/ezr272
  5. Hung JJ, Yeh YC, Jeng WJ, Wu YC, Chou TY, Hsu WH. Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller. Eur J Cardiothorac Surg 2016;50:329-36. https://doi.org/10.1093/ejcts/ezv485
  6. Kanzaki R, Higashiyama M, Fujiwara A, et al. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: risk factors, pattern, and histopathological study. Lung Cancer 2011;71:333-7. https://doi.org/10.1016/j.lungcan.2010.06.008
  7. Li L, Ren S, Zhang Y, et al. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic. Lung Cancer 2013;81:213-7. https://doi.org/10.1016/j.lungcan.2013.04.012
  8. Lin JT, Yang XN, Zhong WZ, et al. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer. Eur J Cardiothorac Surg 2016;50:914-9. https://doi.org/10.1093/ejcts/ezw109
  9. Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2013;44:83-7. https://doi.org/10.1093/ejcts/ezs604
  10. Moon Y, Kim KS, Lee KY, Sung SW, Kim YK, Park JK. Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg 2016;101:1928-35. https://doi.org/10.1016/j.athoracsur.2015.11.056
  11. Wang L, Jiang W, Zhan C, et al. Lymph node metastasis in clinical stage IA peripheral lung cancer. Lung Cancer 2015;90:41-6. https://doi.org/10.1016/j.lungcan.2015.07.003
  12. Ye B, Cheng M, Li W, et al. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 2014;98:217-23. https://doi.org/10.1016/j.athoracsur.2014.03.005
  13. Yeh YC, Kadota K, Nitadori J, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. Eur J Cardiothorac Surg 2016;49:e9-15. https://doi.org/10.1093/ejcts/ezv316
  14. Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. J Thorac Oncol 2012;7:1246-51. https://doi.org/10.1097/JTO.0b013e31825871de
  15. Haruki T, Aokage K, Miyoshi T, et al. Mediastinal nodal involvement in patients with clinical stage I non-small-cell lung cancer: possibility of rational lymph node dissection. J Thorac Oncol 2015;10:930-6. https://doi.org/10.1097/JTO.0000000000000546
  16. Cao J, Xu J, He Z, et al. Prognostic impact of lymphadenectomy on outcomes of sublobar resection for stage IA non-small cell lung cancer ≤2 cm. J Thorac Cardiovasc Surg 2018;156:796-805. https://doi.org/10.1016/j.jtcvs.2018.03.122
  17. Stiles BM, Mao J, Harrison S, et al. Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer ≤2 cm. J Thorac Cardiovasc Surg 2019;157:2454-65. https://doi.org/10.1016/j.jtcvs.2019.01.136
  18. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662-70. https://doi.org/10.1016/j.jtcvs.2010.11.008
  19. Izbicki JR, Thetter O, Habekost M, et al. Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. Br J Surg 1994;81:229-35. https://doi.org/10.1002/bjs.1800810223
  20. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg 1998;22:290-4. https://doi.org/10.1007/s002689900384
  21. Wu Yl, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002;36:1-6. https://doi.org/10.1016/S0169-5002(01)00445-7
  22. Zhang J, Mao T, Gu Z, Guo X, Chen W, Fang W. Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: results of a prospective randomized trial. Thorac Cancer 2013;4:416-21. https://doi.org/10.1111/1759-7714.12040
  23. Huang X, Wang J, Chen Q, Jiang J. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014;9:e109979. https://doi.org/10.1371/journal.pone.0109979
  24. Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis. Eur J Cardiothorac Surg 2017;51:1149-56. https://doi.org/10.1093/ejcts/ezw439
  25. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006;61:597-603. https://doi.org/10.1136/thx.2005.051995
  26. Ding N, Pang Z, Zhang X, et al. Prognostic and predictive effects of positive lymph node number or ratio in NSCLC. Sci Rep 2017;7:584. https://doi.org/10.1038/s41598-017-00619-5
  27. Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER Database and a Chinese multi-institutional registry. J Clin Oncol 2017;35:1162-70. https://doi.org/10.1200/JCO.2016.67.5140
  28. Nwogu CE, Groman A, Fahey D, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg 2012;93:1614-9. https://doi.org/10.1016/j.athoracsur.2012.01.065
  29. Qiu C, Dong W, Su B, Liu Q, Du J. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer. J Thorac Oncol 2013;8:429-35. https://doi.org/10.1097/JTO.0b013e3182829c16
  30. Wang CL, Li Y, Yue DS, Zhang LM, Zhang ZF, Sun BS. Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients. World J Surg 2012;36:455-62. https://doi.org/10.1007/s00268-011-1360-8
  31. Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. Ann Thorac Surg 2006;81:1028-32. https://doi.org/10.1016/j.athoracsur.2005.09.078
  32. Adachi H, Sakamaki K, Nishii T, et al. Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol 2017;12:85-93. https://doi.org/10.1016/j.jtho.2016.08.127
  33. Hishida T, Miyaoka E, Yokoi K, et al. Lobe-specific nodal dissection for clinical stage I and II NSCLC: Japanese multi-institutional retrospective study using a propensity score analysis. J Thorac Oncol 2016;11:1529-37. https://doi.org/10.1016/j.jtho.2016.05.014
  34. Liang RB, Yang J, Zeng TS, et al. Incidence and distribution of lobe-specific mediastinal lymph node metastasis in non-small cell lung cancer: data from 4511 resected cases. Ann Surg Oncol 2018;25:3300-7. https://doi.org/10.1245/s10434-018-6394-9
  35. Hishida T, Saji H, Watanabe SI, et al. A randomized phase III trial of lobe-specific vs. systematic nodal dissection for clinical stage I-II non-small cell lung cancer (JCOG1413). Jpn J Clin Oncol 2018;48:190-4. https://doi.org/10.1093/jjco/hyx170